Herpes Simplex Virus Drug Resistance EQA/PT Scheme

To assess the performance of laboratories in the detection of drug resistance mutations in the herpes simplex virus thymidine kinase (UL23), DNA polymerase (UL30), helicase (UL5) and primase (UL52) genes using sequencing techniques.

Total Number of Challenges: 1
Number of Panel Members: 4
Distribution / Testing Period: Q1
Sample NA Target Source Cultured and/or Clinical material
Matrix Panel Format Transport Medium
Panel Member Target Range Various mutations – Thymidine Kinase (UL23) and DNA polymerase (UL30), helicase (UL5) and primase (UL52)
Panel Member Sample Volume 1.0 ml
Panel Sample Pre-treatment Requirement Ready for analysis. Treat as clinical samples and analyse accordingly.
Panel Analysis Type Sequence Analysis
Panel Testing Evaluated by various molecular methodologies
Storage / Shipment Conditions <-20°C / Frozen on Dry-ice
Accreditation / Regulatory Status Accredited to ISO 17043
SKU: QAV164184_1 Categories: , , , , , Tags: ,

$1,426.53